Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 413.12
ACHN's Cash to Debt is ranked higher than
76% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. ACHN: 413.12 )
ACHN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 413.12

F-Score: 2
Z-Score: 48.16
M-Score: -3.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -45.48
ACHN's ROE (%) is ranked higher than
66% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. ACHN: -45.48 )
ACHN' s 10-Year ROE (%) Range
Min: -199.15   Max: -46.56
Current: -45.48

-199.15
-46.56
ROA (%) -42.46
ACHN's ROA (%) is ranked higher than
64% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. ACHN: -42.46 )
ACHN' s 10-Year ROA (%) Range
Min: -181.02   Max: -43.23
Current: -42.46

-181.02
-43.23
ROC (Joel Greenblatt) (%) -4728.37
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. ACHN: -4728.37 )
ACHN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6066.62   Max: -465.75
Current: -4728.37

-6066.62
-465.75
EBITDA Growth (3Y)(%) 1.00
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ACHN: 1.00 )
ACHN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 4.1
Current: 1

0
4.1
EPS Growth (3Y)(%) 0.50
ACHN's EPS Growth (3Y)(%) is ranked higher than
79% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ACHN: 0.50 )
ACHN' s 10-Year EPS Growth (3Y)(%) Range
Min: -65.5   Max: 3.4
Current: 0.5

-65.5
3.4
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ACHN Guru Trades in Q2 2014

Paul Tudor Jones 26,592 sh (New)
Steven Cohen 547,200 sh (unchged)
Chuck Royce 2,262 sh (-99.55%)
» More
Q3 2014

ACHN Guru Trades in Q3 2014

Jim Simons 897,300 sh (New)
Steven Cohen 1,048,100 sh (+91.54%)
Paul Tudor Jones 45,217 sh (+70.04%)
Chuck Royce 2,262 sh (unchged)
» More
Q4 2014

ACHN Guru Trades in Q4 2014

John Burbank 36,104 sh (New)
John Burbank 207,000 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
Steven Cohen 621,900 sh (-40.66%)
Paul Tudor Jones 13,942 sh (-69.17%)
» More
Q1 2015

ACHN Guru Trades in Q1 2015

John Burbank Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.00
ACHN's P/B is ranked higher than
73% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. ACHN: 4.00 )
ACHN' s 10-Year P/B Range
Min: 0.79   Max: 17.77
Current: 4

0.79
17.77
EV-to-EBIT -10.61
ACHN's EV-to-EBIT is ranked higher than
50% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACHN: -10.61 )
ACHN' s 10-Year EV-to-EBIT Range
Min: -25.5   Max: 0.6
Current: -10.61

-25.5
0.6
Current Ratio 19.64
ACHN's Current Ratio is ranked higher than
94% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ACHN: 19.64 )
ACHN' s 10-Year Current Ratio Range
Min: 1.06   Max: 19.64
Current: 19.64

1.06
19.64
Quick Ratio 19.64
ACHN's Quick Ratio is ranked higher than
94% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ACHN: 19.64 )
ACHN' s 10-Year Quick Ratio Range
Min: 1.06   Max: 19.64
Current: 19.64

1.06
19.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.50
ACHN's Price/Net Cash is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. ACHN: 4.50 )
ACHN' s 10-Year Price/Net Cash Range
Min: 0.82   Max: 12.7
Current: 4.5

0.82
12.7
Price/Net Current Asset Value 4.40
ACHN's Price/Net Current Asset Value is ranked higher than
88% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. ACHN: 4.40 )
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 0.78   Max: 12.29
Current: 4.4

0.78
12.29
Price/Tangible Book 4.00
ACHN's Price/Tangible Book is ranked higher than
78% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. ACHN: 4.00 )
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 77.75
Current: 4

0.72
77.75
Earnings Yield (Greenblatt) -9.80
ACHN's Earnings Yield (Greenblatt) is ranked higher than
64% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. ACHN: -9.80 )
ACHN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.8   Max: 2697.4
Current: -9.8

-9.8
2697.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 

More From Other Websites
The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion... May 21 2015
Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with J&J - Analyst... May 20 2015
Will the J&J Deal With Achillion Transform the Hep C Market? May 20 2015
Johnson & Johnson's big plans May 20 2015
Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat... May 20 2015
Achillion Pharma downgraded by JMP Securities May 20 2015
Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen May 19 2015
Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen May 19 2015
Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 15.3% - Tale of the Tape May 19 2015
Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest May 19 2015
ACHILLION PHARMACEUTICALS INC Financials May 15 2015
10-Q for Achillion Pharmaceuticals, Inc. May 10 2015
Achillion Reports First Quarter 2015 Financial Results May 07 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
Achillion reports 1Q loss May 07 2015
Achillion reports 1Q loss May 07 2015
Achillion Reports First Quarter 2015 Financial Results May 07 2015
Gilead, Achillion Pharma In Race Against Time To Lower HCV Treatment Duration May 01 2015
Achillion to Present at Two Upcoming Investor Conferences Apr 30 2015
Achillion to Present at Two Upcoming Investor Conferences Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK